{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Axsome Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"AXSM"},"Address":{"label":"Address","value":"22 CORTLANDT STREET 16TH FLOOR, NEW YORK, New York, 10007, United States"},"Phone":{"label":"Phone","value":"+1 212 332-3241"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14."},"CompanyUrl":{"label":"Company Url","value":"https://www.axsome.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Amanda Jones","title":"Senior Vice President-Clinical Development"},{"name":"Herriott Tabuteau","title":"Chairman &amp; Chief Executive Officer"},{"name":"Mark L. Jacobson","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}